ADC Therapeutics (NYSE: ADCT) Exceeds Q3 2026 Earnings Expectations with ZYNLONTA Growth
Key points
- Adjusted loss per share of $0.16 was smaller than the $0.21 analyst estimate.
- Revenue reached $21.72 million, surpassing the $18.7 million estimate.
- ADC Therapeutics holds $189.2 million in cash, extending its operational funding into 2029.
ADC Therapeutics (NYSE: ADCT) is a drug company developing treatments for blood cancers. Its main product, ZYNLONTA, treats certain B-cell cancers. In the third quarter of 2026, the company reports an adjusted loss of $0.16 per share, smaller than the $0.21 loss analysts expected, as highlighted by Zacks.
The quarterly loss also narrows from $0.30 per share a year earlier. Revenue reaches $21.72 million, up from $16.43 million and above the $18.7 million estimate. ADC Therapeutics beats both earnings-per-share and revenue estimates in three of the past four quarters.
Net product revenue totals $21 million for the quarter. ADC Therapeutics holds $189.2 million in cash and cash equivalents as of September 30. The company says a financial restructuring strengthens its balance sheet and gives it enough expected cash to fund operations into 2029.
ADC Therapeutics continues to study ZYNLONTA for other B-cell cancers, with research scheduled for presentation at ASH 2026. In Japan, partner Tanabe’s application for marketing authorization could support future regulatory and sales milestones. The stock’s price-to-sales ratio is 2.24, meaning its market value is 2.24 times its annual sales.
Read the rest, free
Pop in your email to read every article in full and search any company. It takes five seconds.
You'll get Gro's newsletter too. Leave any time in one click.
